TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TELA Bio is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 am ET. The company focuses on innovative soft-tissue reconstruction technologies that enhance clinical outcomes by prioritizing the preservation of the patient's anatomy. Interested individuals can access the live and archived webcast through ir.telabio.com. TELA Bio is committed to offering economically effective solutions that utilize the patient's natural healing response, minimizing reliance on synthetic materials.
Details
News Market Reaction – TELA
The recorded move for TELA in the trading session of this news was +2.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 12th, 2023.
TELA’s management is scheduled to present at 11:15 am ET on January 12th, 2023. Interested parties can access the live and archived webcast at ir.telabio.com.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.